Renal Pharmacology · Module 1 of 5

Loop Diuretics and Thiazides

Mechanisms, electrolyte consequences, and clinical applications · Nephron segmental targets · Calcium effects · Diuretic resistance

The nephron segments targeted by diuretics determine both efficacy and electrolyte consequences. Proximal convoluted tubule (~65% Na): NHE3 + carbonic anhydrase → target of carbonic anhydrase inhibitors. Thick ascending limb (~25% Na): NKCC2 cotransporter — water-impermeable segment that builds the medullary gradient → target of loop diuretics; blockade collapses the gradient and delivers the most powerful natriuresis of any class. Distal convoluted tubule (~7% Na): NCC cotransporter → target of thiazides; electroneutral transport, modest natriuresis, well-suited for sustained blood pressure control. Collecting duct (~2% Na): ENaC regulated by aldosterone → target of potassium-sparing diuretics. Loop diuretics reach the lumen by active secretion via organic anion transporters (OATs) on the proximal tubule basolateral membrane, not by glomerular filtration — a key pharmacokinetic fact explaining CKD dose-resistance.
Loop diuretics (furosemide, torsemide, bumetanide, ethacrynic acid): block NKCC2 at its chloride-binding site → abolish lumen-positive potential in the thick ascending limb → impair paracellular reabsorption of Ca²⁺ and Mg²⁺ (calciuresis + magnesiuresis). Sigmoidal dose-response: no effect below threshold luminal concentration; no additional effect above ceiling. In CKD, competing endogenous organic anions crowd out the diuretic at OATs → higher threshold, lower ceiling natriuresis → escalate dose to threshold. Furosemide: highly variable oral bioavailability (10–90%); IV preferred in acute decompensated heart failure. Torsemide: oral bioavailability 80–90%; t½ 3–4 h; hepatic metabolism — more predictable in renal impairment. TRANSFORM-HF: no mortality difference furosemide vs torsemide. Ethacrynic acid: only non-sulfonamide loop diuretic; use in sulfonamide allergy; highest ototoxicity risk. Ototoxicity amplified by concurrent aminoglycosides (additive cochlear hair cell damage).
Thiazides (hydrochlorothiazide, chlorthalidone) and thiazide-like agents (metolazone): block NCC in the distal convoluted tubule. Electroneutral blockade → no paracellular calcium wasting. Instead: ↓ intracellular Na → enhanced basolateral NCX → draws Ca²⁺ into cells via apical TRPV5 → calcium retention (hypocalciuria) — opposite of loop diuretics. Chlorthalidone: t½ 40–60 h (vs hydrochlorothiazide 6–15 h) → superior 24-h BP coverage; ALLHAT trial: chlorthalidone-based therapy reduced cardiovascular events more effectively than amlodipine or lisinopril — preferred thiazide for hypertension. Metolazone: retains efficacy at GFR <30 mL/min (partial proximal tubular action) → used almost exclusively as add-on to loop diuretics in diuretic resistance (sequential nephron blockade); monitor electrolytes and renal function within 24–48 h of initiation.
Electrolyte complications — both classes: hypokalemia (loop: ↑ Na delivery to collecting duct → electrogenic ENaC stimulation → ROMK-mediated K⁺ secretion; thiazide: volume → secondary aldosteronism → ENaC + ROMK upregulation); hypomagnesemia (loop: abolish lumen-positive potential → impair paracellular Mg²⁺ in TAL; thiazide: downregulate TRPM6 channel in DCT); metabolic alkalosis (NHE3 upregulation, hypokalemia, secondary aldosteronism); hyperuricemia (compete with urate at OATs in PCT → ↓ urate secretion; volume contraction upregulates URAT1 → ↑ urate reabsorption). Thiazide-specific: hyponatremia (impair dilution but preserve medullary gradient → intact ADH-driven concentration → profound hyponatremia; loop diuretics collapse the gradient → near-isotonic urine regardless of ADH → much less hyponatremia risk; elderly women on thiazides = classic at-risk group); glucose intolerance (hypokalemia impairs beta-cell insulin secretion).
Refractory hypokalemia rule: magnesium depletion keeps ROMK open regardless of K⁺ supplementation — replace Mg²⁺ first, then K⁺ will respond. Drug interactions: NSAIDs inhibit COX-dependent renal prostaglandins → ↓ GFR, ↑ tubular Na reabsorption → blunt diuretic response; lithium toxicity (both classes upregulate NHE3 → reabsorb Li⁺ with Na⁺; thiazides can double/triple lithium levels; if diuretic needed, amiloride preferred); digoxin toxicity amplified by diuretic-induced hypokalemia and hypomagnesemia (both cations compete with digoxin for Na⁺/K⁺-ATPase binding). Clinical applications: loop diuretics for acute heart failure (IV furosemide; DOSE trial: 2.5× oral dose IV → greater fluid loss vs low-dose); loop diuretics for acute hypercalcemia (after IV saline resuscitation); chlorthalidone for hypertension (ALLHAT); thiazides for calcium nephrolithiasis prevention (−30–50% urinary Ca); metolazone for diuretic resistance.

ADH = antidiuretic hormone · CKD = chronic kidney disease · DCT = distal convoluted tubule · ENaC = epithelial sodium channel · GFR = glomerular filtration rate · NCC = sodium-chloride cotransporter · NCX = sodium-calcium exchanger · NHE3 = sodium-hydrogen exchanger isoform 3 · NKCC2 = Na-K-2Cl cotransporter isoform 2 · OAT = organic anion transporter · PCT = proximal convoluted tubule · ROMK = renal outer medullary potassium channel · TAL = thick ascending limb · TRPM6 = transient receptor potential melastatin 6 · TRPV5 = transient receptor potential vanilloid 5 · URAT1 = urate transporter 1

Nephron Segmental Targets by Diuretic Class

Segment	% Na	Transporter	Diuretic Class	Key Feature
Proximal convoluted tubule	~65%	NHE3 + carbonic anhydrase	Carbonic anhydrase inhibitors	Bicarbonate reclamation coupled to Na reabsorption
Thick ascending limb	~25%	NKCC2 — water-impermeable; builds medullary gradient	Loop diuretics — most potent class	Secreted via OATs, not filtered; calciuresis + magnesiuresis
Distal convoluted tubule	~7%	NCC — electroneutral	Thiazides — modest natriuresis; sustained BP control	Calcium retention (hypocalciuria) — opposite of loop diuretics
Collecting duct	~2%	ENaC — regulated by aldosterone	Potassium-sparing diuretics	Electrogenic — drives K⁺ secretion via ROMK

Loop Diuretics

Mechanism

NKCC2 Blockade

Block NKCC2 at its chloride-binding site → 1 Na, 1 K, 2 Cl entry abolished per transport cycle
Abolishes lumen-positive electrical potential in TAL → impairs paracellular Ca²⁺ and Mg²⁺ reabsorption → calciuresis + magnesiuresis
Collapses medullary concentration gradient → near-isotonic urine regardless of ADH
Most potent natriuresis of any diuretic class (~25% of filtered Na blocked)

Pharmacokinetics

OAT Secretion and CKD Resistance

Reach lumen via active secretion through OATs on proximal tubule basolateral membrane — not glomerular filtration
CKD: competing endogenous organic anions crowd out drug at OATs → lower luminal concentration → higher threshold, lower ceiling natriuresis
Dose-response: sigmoidal curve — no effect below threshold; no added effect above ceiling
Response to CKD resistance: escalate dose to threshold, not beyond ceiling

Individual Agents

Furosemide, Torsemide, Others

Furosemide: highly variable oral bioavailability (10–90%); IV preferred in acute decompensated HF; DOSE trial: 2.5× oral dose IV → greater fluid loss
Torsemide: oral bioavailability 80–90%; t½ 3–4 h; hepatic metabolism → more predictable in CKD; TRANSFORM-HF: no mortality difference
Bumetanide: ~40× more potent than furosemide mg-for-mg; superior oral bioavailability
Ethacrynic acid: only non-sulfonamide loop diuretic (sulfonamide allergy); highest ototoxicity risk; additive with aminoglycosides

Thiazide and Thiazide-Like Diuretics

Mechanism

NCC Blockade — Calcium Retention

Block NCC (electroneutral) in distal convoluted tubule → no lumen-positive potential → no paracellular Ca²⁺ wasting
↓ intracellular Na → enhanced basolateral Na-Ca exchange → draws Ca²⁺ into cell via apical TRPV5 channel
Net: calcium retention (hypocalciuria) — opposite of loop diuretics
Use: calcium nephrolithiasis prevention (reduce urinary Ca 30–50%)
Contraindicated: hypercalcemia

Preferred Agent — Hypertension

Chlorthalidone

Thiazide-like agent; t½ 40–60 h (vs hydrochlorothiazide 6–15 h) → superior 24-h BP coverage
ALLHAT trial: chlorthalidone-based therapy reduced CV events more than amlodipine or lisinopril in high-risk hypertensive patients
Guideline-preferred thiazide for hypertension
More consistent natriuresis and antihypertensive effect than hydrochlorothiazide

Diuretic Resistance

Metolazone

Thiazide-like; retains efficacy at GFR <30 mL/min (partial proximal tubular action)
Used almost exclusively as add-on to loop diuretics in refractory volume overload — sequential nephron blockade
Combination can produce dramatic natriuresis — monitor electrolytes and renal function within 24–48 h of initiation
Not used as primary antihypertensive

Calcium Effects — Opposite Between Classes

	Loop Diuretics	Thiazides
Mechanism	Abolish lumen-positive potential in TAL → impair paracellular Ca²⁺ reabsorption	↓ intracellular Na in DCT → enhanced basolateral NCX → ↑ TRPV5-mediated luminal Ca²⁺ entry
Calcium effect	Calciuresis — increased urinary calcium loss	Hypocalciuria — calcium retention in body
Clinical use	Acute hypercalcemia (after IV saline resuscitation)	Calcium nephrolithiasis prevention (−30–50% urinary Ca)
Contraindication	Calcium nephrolithiasis	Hypercalcemia (would worsen)

Electrolyte Complications and Drug Interactions

Shared Electrolyte Complications

Both Loop Diuretics and Thiazides

Hypokalemia — loop: ↑ Na delivery to collecting duct → electrogenic ENaC → ROMK K⁺ secretion; thiazide: volume → secondary aldosteronism → ENaC + ROMK upregulation
Hypomagnesemia — loop: abolish paracellular Mg²⁺ in TAL; thiazide: downregulate TRPM6 channel in DCT
Metabolic alkalosis — NHE3 upregulation + hypokalemia (H⁺-K⁺ exchange) + aldosterone-driven H⁺ secretion
Hyperuricemia — compete with urate at OATs in PCT (↓ secretion); volume contraction upregulates URAT1 (↑ reabsorption)
Hyponatremia — thiazide-specific risk; impairs dilution but preserves medullary gradient → concentrated urine + ADH → profound hyponatremia; loop diuretics collapse gradient → less hyponatremia risk

Key Drug Interactions

NSAIDs, Lithium, Digoxin, Aminoglycosides

NSAIDs: inhibit renal prostaglandins → ↓ GFR + ↑ tubular Na reabsorption → blunt diuretic response; frequently overlooked with OTC NSAID use
Lithium toxicity: both classes upregulate NHE3 → reabsorb Li⁺ with Na⁺; thiazides can double/triple lithium levels within days; if diuretic needed in lithium patient → amiloride preferred
Digoxin toxicity: hypokalemia + hypomagnesemia lower toxic threshold (both cations compete with digoxin for Na⁺/K⁺-ATPase); monitor digoxin levels and electrolytes
Aminoglycosides + loop diuretics: additive cochlear hair cell damage → amplified ototoxicity risk; avoid combination when possible

Refractory Hypokalemia — Replete Magnesium First

When potassium supplementation fails to correct hypokalemia in a patient on diuretics, check serum magnesium before escalating potassium replacement. Magnesium depletion keeps the ROMK channel in the collecting duct constitutively open — preventing adequate suppression of potassium secretion regardless of how much potassium is replaced. Correct the magnesium deficit first, and serum potassium will respond to standard replacement doses.

Diuretic Resistance — Six Questions Before Adding Metolazone

Before labeling inadequate diuresis as "resistance" and escalating to sequential nephron blockade, confirm: (1) bioavailability — switch to IV if bowel edema is possible; (2) dose is above the threshold for that patient's renal function, not merely above the prior dose; (3) dosing frequency matches the drug's duration of action to minimize post-diuretic sodium avidity; (4) no concurrent NSAIDs, contrast agents, or aminoglycosides blunting the response; (5) potassium and magnesium have been repleted; (6) hypoalbuminemia has been considered as a pharmacokinetic barrier (free drug reduced). Only after these steps should metolazone be added — and when it is, monitor renal function and electrolytes within 24–48 hours.

Suggested References

Author / Source	Title	Publication
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Ellison DH, Felker GM	Diuretic treatment in heart failure	N Engl J Med. 2017;377(20):1964–1975
Hoorn EJ, Ellison DH	Diuretic resistance	Am J Kidney Dis. 2017;69(1):136–142
Bhalla V, Hallows KR	Mechanisms of ENaC regulation and clinical implications	J Am Soc Nephrol. 2008;19(10):1845–1854
Brater DC	Diuretic therapy	N Engl J Med. 1998;339(6):387–395
Felker GM, Lee KL, Bull DA, et al	Diuretic strategies in patients with acute decompensated heart failure (DOSE)	N Engl J Med. 2011;364(9):797–805
Mentz RJ, Anstrom KJ, Eisenstein EL, et al	Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial	JAMA. 2023;329(3):214–223
Fink HA, Akornor JW, Garimella PS, et al	Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials	Eur Urol. 2009;56(1):72–80
ALLHAT Officers and Coordinators	Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic	JAMA. 2002;288(23):2981–2997
Liamis G, Milionis H, Elisaf M	A review of drug-induced hyponatremia	Am J Kidney Dis. 2008;52(1):144–153
Zillich AJ, Garg J, Basu S, et al	Thiazide diuretics, potassium, and the development of diabetes: a quantitative review	Hypertension. 2006;48(2):219–224